Ocimum Acquires Isogen's Biomolecular Synthesis Division to Grow Oligo Play | GenomeWeb

Ocimum Acquires Isogen's Biomolecular Synthesis Division to Grow Oligo Play

Nov 17, 2006

NEW YORK (GenomeWeb News) — Ocimum Biosolutions has acquired the biomolecular synthesis segment of Dutch company Isogen Life Sciences, Ocimum said today.

Ocimum CEO Anuradha Acharya said the acquisition is “a significant step towards becoming a global oligo player,” and said the company will continue to look for strategic targets to expand its oligo-production capacity.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Threats of Synthetic Biology

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

Deletion Is Hard to Do

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

So Just How Many Are There?

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

This Week in Genome Research

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.